• Pria Anand, Michaël C C Slama, Michelle Kaku, Charlene Ong, Anna M Cervantes-Arslanian, Lan Zhou, William S David, and Amanda C Guidon.
• Department of Neurology, Boston University Medical Center, Boston, Massachusetts.
• Muscle Nerve. 2020 Aug 1; 62 (2): 254-258.

IntroductionCoronavirus disease 2019 (COVID-19) has rapidly become a global pandemic, but little is known about its potential impact on patients with myasthenia gravis (MG).MethodsWe studied the clinical course of COVID-19 in five hospitalized patients with autoimmune MG (four with acetylcholine receptor antibodies, one with muscle-specific tyrosine kinase antibodies) between April 1, 2020-April 30-2020.ResultsTwo patients required intubation for hypoxemic respiratory failure, whereas one required significant supplemental oxygen. One patient with previously stable MG had myasthenic exacerbation. One patient treated with tocilizumab for COVID-19 was successfully extubated. Two patients were treated for MG with intravenous immunoglobulin without thromboembolic complications.DiscussionOur findings suggest that the clinical course and outcomes in patients with MG and COVID-19 are highly variable. Further large studies are needed to define best practices and determinants of outcomes in this unique population.© 2020 Wiley Periodicals, Inc.

52 keywords...

hide…